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ABSTRACT
Objective: The objective of this study was to estimate homocysteine levels in myocardial infarction (MI) patients (troponin-T positive) and normal 
healthy individuals (troponin-T negative) subsequently to make comparisons with other cardiac markers.
Methods: A cross-sectional study consisting of 172 subjects involving 100 patients of non-diabetic MI and 72 apparently healthy controls with no 
history of diabetes and/or MI was done between December 2017 and May 2018. The diagnosis of MI was established with electrocardiogram findings 
and troponin-T estimation. Blood samples were collected and processed for the estimation of homocysteine, troponin-T, creatine kinase MB fraction 
(CK-MB), and lactate dehydrogenase.
Results: In the present study, a total of 100 troponin-T positive cases and 72 troponin-T negative as controls were studied. The mean age in the 
cases was 62.15±7.75 years and in the controls was 61.49±8.35 years (p=0.592). The mean value of homocysteine in the troponin-T positive group 
was 30.56±19.79 µmol/l and in the troponin-T negative group was 10.28±4.03 µmol/l (p<0.0001). Homocysteine was deranged in 98% troponin-T 
positive group and in only 18.06% in troponin-T negative group. The difference was statistically significant (p<0.0001). No significant correlation was 
found between homocysteine and CK-MB and LDH in troponin-T positive and negative patients individually.
Conclusion: This study indicated that homocysteine is sensitive cardiac markers for the diagnosis of MI but shows no specific correlation with other 
cardiac markers and thus it should be predicted independently.
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INTRODUCTION
Myocardial infarction (MI) or acute coronary syndromes (ACS) remains 
the major clinical event in patients with atherosclerosis of the coronary 
arteries [1]. Cardiovascular disease, especially coronary heart disease 
(CHD), is epidemic in India. According to the Registrar General of India 
reports, CHD led to 17% of total deaths and 26% of adult deaths in 
2001–2003, which increased to 23% of total and 32% of adult deaths 
in 2010–2013 [2]. In the younger age population, the rate of acute MI 
(AMI) is 5% [3].
The diagnosis of AMI requires multidimensional approach of physical 
examination and clinical symptoms assessment, electrocardiogram 
(ECG) examination, and laboratory marker studies. The effective 
management should involve the laboratory markers results and risk 
stratification. Even among patients with ST-segment elevated MI, 
for whom initial therapeutic options are well defined, patient risk 
characteristics impact the short and long-term medical decision-
making [4].
Analysis of cardiac biomarkers has become the front-line diagnostic 
tools for AMI and has enabled the doctors in the rapid diagnosis and 
treatment planning, thereby reducing the mortality rate by a great 
extent. However, the future of cardiac biomarkers will follow the 
analysis of a panel of markers for the diagnosis and prognosis of MI.
Homocysteine, a newer cardiac marker, is quite promising in this aspect 
apart from other routinely used markers such as lactate dehydrogenase 
(LDH), aspartate aminotransferase (AST), creatine kinase MB 
fraction (CPK-MB), and C-reactive protein (CRP). Since McCully [5] 
first proposed the homocysteine theory of atherosclerosis, a lot of 
observational studies have reported a relation between blood levels of 
homocysteine and CHD [6].
Thus, this observational study was undertaken to see the levels of 
inflammatory marker. Homocysteine as an independent predictor of 
coronary artery disease (CAD) and its relationship with other cardiac 
biomarkers such as CRP, AST, LDH, troponin, and CK-MB to suggest a 
future panel of cardiac biomarkers for diagnosis of MI.
METHODS
A cross-sectional study was conducted in the department of 
biochemistry in a tertiary care hospital. A total of 172 patients were 
included in this study and were divided into two groups. Group I 
(Cases) - consisted of 100 diagnosed cases of non-diabetic MI admitted 
to emergency and intensive care unit of the Santosh Medical College 
Hospital and RC Ghaziabad. Group II (controls) - consisted of 72 healthy 
subjects with no history of diabetes and/or MI. Informed consent was 
obtained from patients. Information extraction forms were used to 
gather data from patient files.
All patients more than 35 years of age (male and female) of confirmed 
non-diabetic MI based on ECG findings and cardiac enzymes (troponin-T) 
were included in the study. Patients with diabetes mellitus having MI, 
recent history of surgery and trauma within the preceding 2 months, 
and renal insufficiency (serum creatinine >1.5 mg/dl), patients with 
cerebrovascular accidents or previous history of cerebrovascular 
accidents, patients having evidence of infections, inflammatory disease, 
and malignancy, patient taking drugs such as Vitamin B-complex or folic 
acid, and hormone replacement therapy, and those who were not willing 
to participate were excluded from the study. The initial evaluation 
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of patients with MI consisted of history, physical examination, ECG 
changes, and laboratory investigation (troponin-T). The blood samples 
were taken from all the cases and controls and were immediately 
analyzed for biochemical parameters.
Under all aseptic precautions, about 5 ml of venous blood samples 
was collected by clean venepuncture in a sterile plain and 
ethylenediaminetetraacetic acid vial. Blood samples were allowed to 
coagulate after which they were centrifuged at 3000 rpm for 5 min to 
obtain serum. The separated clear serum was transferred into sterile 
bottles and used for the enzyme assay. When not used immediately, 
they were kept at −20°C and later used within 5 days.
Measurement of troponin-T was done qualitatively by rapid test 
kit method manufacturing by Roche Diagnostics International Ltd., 
CH-6343 Rotkreuz, Switzerland. Measurement of CK-MB and LDH was 
done by the International Federation of Clinical Chemistry protocol. 
Commercial kit produced by Transasia Biomedical Ltd. (H.P.) was used. 
Serum homocysteine level was estimated in serum sample using enzyme-
linked immunosorbent assay (ELISA). ELISA kit by Qayee-Bio Ltd., China, 
and ELISA reader of Robonik (India) Pvt., Ltd., were used in this study.
Statistical analysis
Categorical variables were presented in number and percentage (%) 
and continuous variables were presented as mean ± SD and median. 
Normality of data was tested by the Kolmogorov–Smirnov test. If 
normality was rejected, then non-parametric test was used.
Statistical tests were applied as follows:
1. Quantitative variables were compared using independent t-test/
Mann–Whitney U-test (when the data sets were not normally 
distributed) between the two groups.
2. Qualitative variables were correlated using Chi-square test/Fisher’s 
exact test.
3. Spearman rank correlation coefficient was used to measure the 
association of various parameters with each other.
4. Univariate logistic regression was used to evaluate significant risk 
factors for troponin-T positive.
p<0.05 was regarded as statistically significant.
The data were entered into MS Excel spreadsheet and analysis was 
done using the Statistical Package for the Social Sciences version 21.0.
RESULTS
In the present study, a total of 100 troponin-T positive cases and 72 
troponin-T negative as controls were studied. The mean age of the cases 
was 62.15±7.75 years and in the controls was 61.49±8.35 years. The 
comparison of mean ages of the two groups has been shown in Table 1. 
In the present study, troponin-T positive group had 29% of females and 
71% of males, whereas the control group had 29.17% of females and 
70.83% of males. The gender distribution and comparison have been 
shown in Table 2.
Homocysteine was deranged in 98% troponin-T positive group and in 
only 18.06% in troponin-T negative group. The comparison has been 
shown in Table 3. The mean value of homocysteine in the troponin-T 
positive group was 30.56±19.79 µmol/l and in the troponin-T negative 
group was 10.28±4.03 µmol/l. The comparison has been shown in 
Table 4.
The mean value of CK-MB and LDH in the troponin-T positive group 
was 111.94±29.59 IU/l and 564.43±110.99 IU/l, whereas in the 
troponin-T negative group was 16.36±3.77 IU/l and 223.68±36.23 IU/l, 
respectively. The comparison has been shown in Table 5.
On comparing homocysteine with other cardiac markers, no significant 
correlation was found between homocysteine and CK-MB, LDH, for 
troponin-T positive patients (p>0.05). It has been shown in Table 6.
On comparing homocysteine with other cardiac markers, no significant 
correlation was found between homocysteine and CK-MB, LDH, for 
troponin-T negative patients (p>0.05). It has been shown in Table 7.
On performing univariate logistic regression, homocysteine levels were 
found to be a significant risk factor of troponin-T positive patients 
(p<0.0001). With the increase in 0.1 unit in homocysteine, risk of 
troponin-T positive patients increased by 12.60%. CK-MB and LDH 
showed a high standard error and thus the regression analysis did not 
show a correlation (Table 8).
Table 1: Mean of age distribution





Mean±SD 61.49±8.35 62.15±7.75 0.592
Median (range) 61.5 (39–76) 62 (42–76)
Interquartile range 56–68 56.500–68
an=72, bn=100
Table 2: Gender distribution
Gender distribution Troponin‑T negativea (%) Troponin‑T positiveb (%) Totalc (%) p value
Female 21 (29.17) 29 (29.00) 50 (29.07) 0.981
Male 51 (70.83) 71 (71.00) 122 (70.93)
an (%), n=72, bn (%), n=100, cn (%), n=172
Table 3: Homocysteine derangement
Homocysteine (µmol/l) Troponin‑T negativea (%) Troponin‑T positiveb (%) Totalc (%) p value
Deranged 13 (18.06) 98 (98.00) 111 (64.53) <0.0001**
Normal 59 (81.94) 2 (2.00) 61 (35.47)
an (%), n=72, bn (%), n=100, cn (%), n=172, **p<0.01
Table 4: Mean distribution of homocysteine
Homocysteine (µmol/l) Troponin‑T negativea Troponin‑T positiveb p value
Mean±SD 10.28±4.03 30.56±19.79 <0.0001**
Median (range) 9.45 (1.7–18.5) 27.6 (13.8–207)
Interquartile range 6.800–13.500 23.700–31.800
an=72, bn=100, **p<0.01
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DISCUSSION
The sociodemographic details of the study were similar. The mean age 
in the cases was 62.15±7.75 years and in the controls was 61.49±8.35 
years. CK-MB, CRP, LDH, and homocysteine values individually showed a 
significant difference among troponin-T positive and negative patients.
In our study, the mean value of homocysteine in the troponin-T positive 
group was 30.56±19.79 µmol/l and in the troponin-T negative group 
was 10.28±4.03 µmol/l. The difference was statistically significant. 
Homocysteine was deranged in 98% troponin-T positive group 
and in only 18.06% in troponin-T negative group. The difference 
was statistically significant. In other similar studies, the mean 
value of homocysteine in the cases was 25.89±6.18 µmol/l [7] and 
24.59±6.14 µmol/l [8] and in the controls was 13.83±3.51 µmol/l [7] 
and 13.73±3.54 µmol/l [8]. The difference was statistically significant 
(p<0.01) as seen in our study. In another study on 100 patients 
by Prajapati and Panjwani, homocysteine values were <13 in 13% 
patients and high in 87% patients. It was more than 50 in 17% of 
patients and 13–50 in 70% of patients. They also concluded that 
hyperhomocysteinemia was more common in vegetarians (78.16%) as 
they lack Vitamin B12 in their diet than non-vegetarians (21.83%) [9]. 
In another study by Sanoli G et al. (2017) [10], the mean plasma level of 
homocysteine in patients (16.88±10.84 μmol/l) was slightly higher than 
the control group (14.18±4.19 μmol/l). His findings were contrary to our 
study as the mean homocysteine values were not significantly different 
among cases and controls. Their results do not support the hypothesis 
that CHD is related to elevated serum homocysteine concentration. The 
results are not conclusive due to the inability to adequately control for 
potential confounding factors as well as inadequate sample size [10].
On performing univariate logistic regression in our study, homocysteine 
levels were significant risk factors of troponin-T positive patients and 
CK-MB and LDH showed high standard error and thus did not show 
correlation. In a meta-analysis conducted by Boushey et al., a study 
conducted by Stampfer et al. and Chamber et al., all showed that 
homocysteine was an independent, risk factor for CHD, and independent 
of conventional risk factors [8]. Ashraf [11] showed homocysteine 
association with troponin-I. An association between homocysteine 
concentrations and plasma markers of thrombosis activation in patients 
admitted for ACS was shown in the study by Al-Obaid et al. [12].
All these studies signify the importance of hyperhomocysteinemia 
as an independent risk factor in AMI, and thus, serum homocysteine 
should be assessed in all MI patients in collaboration with other cardiac 
biomarkers such as CK-MB and LDH.
Homocysteine induces atherogenesis by mechanisms such as 
endothelial injury, platelet activation, smooth muscle proliferation, 
oxidative modification of low-density lipoproteins (LDL), and 
endothelial leukocyte interactions as shown in Flowchart 1 [13].
Homocysteine is known to induce atherothrombosis in many ways: Like 
homocysteine thiolactate, a by-product of oxidation of homocysteine 
which combines with LDL to form foam cells. LDL-rich foam cells then get 
embedded in the vascular endothelium and become fatty streak, which is 
the starting of an atherosclerotic plaque. Homocysteine thiolactate has 
also been suggested to impair oxidative phosphorylation and enhance 
proliferation and fibrosis of smooth muscle cells in the vessels [8].
One mechanism is that the homocysteine reduces the concentration of 
high-density lipoprotein (HDL) cholesterol in plasma by inhibiting the 
hepatic synthesis of apo A-I, the main HDL apolipoprotein. HDL which 
is a good cholesterol and maintains the reverse cholesterol transport 
is decreased and chances of atheroma start increasing. Elevated 
homocysteine also causes endothelial cell injury which is followed by 
platelet aggregation and thrombus formation and last atherosclerosis [9].
Homocysteine enhances lipid peroxidation which may decrease the 
expression of endothelial nitrous oxide (NO) synthase and directly 
degrade NO. Autoxidation of homocysteine results in oxidation of LDL 
through generation of the superoxide anion radical. Homocysteine may 
also reduce the antioxidant status which could injure endothelial cells. 
Homocysteine stimulates platelet generation of thromboxane A2, which 
is a vasoconstrictor and proaggregant [8].
Studies on the association of hyperhomocysteinemia with CAD in 
different populations have yielded different results with some studies 
providing evidence for an association while others have not. This may 
be due to ethnic or geographical differences or due to differences in the 
case selection. As genetic background and nutritional intake vary in 
different populations, the homocysteine level varies in different ethnic 
groups and this may be due to the polymorphism seen in the genes 
encoding enzymes involved in the metabolism of homocysteine [8].
Our study results should be read within the context of several 
limitations. First, the study design prevents the inference of causal 
relationships among variables. Our findings of a strong association 
of serum homocysteine with the cardiac biomarkers and Troponin-T 
positivity indirectly highlight the significance of levels of serum 








CK-MB (IU/l) 16.36±3.77 111.94±29.59 <0.0001**
LDH (IU/l) 223.68±36.23 564.43±110.99
aMean±SD, n=72, bmean±SD, n=100, **p<0.01
Table 6: Homocysteine correlation with CK‑MB and LDH in 
troponin‑T positive patients
Cardiac markers Correlation coefficient p value
CK-MB (IU/l) 0.002 0.982
LDH (IU/l) −0.075 0.457
Table 7: Homocysteine correlation with CK‑MB and LDH in 
troponin‑T negative patients
Cardiac markers Correlation coefficient p value
CK-MB (IU/l) −0.184 0.122
LDH (IU/l) −0.099 0.410
Table 8: Univariate logistic regression of troponin‑T positive patients
Parameters B‑error Standard error p‑value Odds ratio 95% Confidence interval for odds ratio
Lower Upper
Age (in year) 0.010 0.019 0.590 1.011 0.973 1.050
CK-MB (IU/l) 1.032 72.093 0.989 2.806 0.000 6.51E+61
LDH (IU/l) 0.596 25.733 0.982 1.815 0.000 1.45E+22
Homocysteine (µmol/l) 0.815 0.191 <0.0001** 2.260 1.554 3.286
**p<0.01
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homocysteine in the extent of myocardial damage and the immediate 
outcomes of patients with ACS. Finally, it is difficult to determine 
whether the results of the study would generalize to other ethnicities 
and geography. Further, research with a larger sample size must be 
made in major areas to confirm the validity of our results.
CONCLUSION
Our study indicated that homocysteine, CK-MB, and LDH are sensitive 
cardiac markers for the diagnosis of MI and can be used as a panel for 
testing for AMI but show no specific correlation with each other, and 
thus, they should be used and predicted independently.
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